ClinicalTrials.gg
CompletedNCT02207907Updated Apr 13, 2017Results posted

To Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste

A Phase 2 interventional study of Sodium bicarbonate plus sodium fluoride and Sodium fluoride in Oral Hygiene, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-13.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objectives of this study will be to compare the Gingival Bleeding and Gingival Inflammation following twice daily use of a sodium bicarbonate experimental dentifrice compared to a 0% sodium bicarbonate toothpaste after 24 weeks of use. The study will be conducted at Silverstone Research Group. Participants will be recruited from their database and by use of an external recruitment agency.

02

Conditions studied

  • Oral Hygiene
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Good general health with (in the opinion of the investigator) no and relevant abnormalities of medical history or oral/dental examination.
  • A minimum of 20 permanent gradable teeth
  • Moderate gingivitis present at the screening visit in the opinion of the investigator
  • A total of 20 bleeding sites or greater at baseline visit
  • Positive response to bleeding on brushing present at the screening visit

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding women
  • Tobacco chewers
  • Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the participant unlikely to fully complete the study or any that increases the risk to the participants or undermines the data validity.
  • Recent history (within the last year) of alcohol or other substance abuse
  • Participants requiring prophylactic antibiotic treatment prior to dental therapy
  • Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients
  • Have current active caries or any medical conditions which may directly influence gingival bleeding
  • Use of concomitant or any systemic medication that, in the opinion of the investigator, might interfere with the outcome of the study or have an effect on gingival conditions within 14 days of gingival examinations
  • Excessive calculus present that interferes with the probing examination for Gingival Bleeding Index
  • Participation in another clinical study or receipt of an drug or oral care product within 30 days of the screening visit
  • An employee of the sponsor or the study site or members or their immediate family.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Sodium bicarbonate plus sodium fluoride

    Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride

    Drug: Sodium bicarbonate plus sodium fluoride

  • Active comparator
    Sodium fluoride

    Toothpaste containing 1100 ppm fluoride as sodium fluoride

    Drug: Sodium fluoride

Interventions

  • DrugSodium bicarbonate plus sodium fluoride

    Drug pages: Sodium Bicarbonate · Sodium Fluoride

    Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride

  • Toothpaste containing 1100 ppm fluoride as sodium fluoride

06

What researchers measure

Primary outcomes

  1. Number of Gingival Bleeding Sites at 24 Weeks

    Number of gingival bleeding sites were measured as bleeding index via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. A bleeding site was considered as a BI score of 1 or 2.

    Time frame: Baseline, 24 weeks

  2. Modified Gingival Index (MGI) at 24 Weeks

    The Modified Gingival Index (MGI) was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

    Time frame: Baseline, 24 weeks

Secondary outcomes

  1. Number of Gingival Bleeding Sites at 6 and 12 Weeks.

    Number of gingival bleeding sites were measured as bleeding index via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. A bleeding site was considered as a BI score of 1 or 2.

    Time frame: Baseline, 6 and 12 weeks

  2. Modified Gingival Index (MGI) at 6 and 12 Weeks.

    MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

    Time frame: Baseline, 6 and 12 weeks

  3. Bleeding Index at 6, 12 and 24 Weeks

    The Bleeding Index was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system to be used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed

    Time frame: Baseline, 6, 12 and 24 weeks

  4. Plaque Control (Overall and Interproximal Dental Plaque Scores) Using Turesky Modification of Quigley &Amp; Hein Plaque Index at 6, 12 and 24 Weeks.

    The dental examiner used the Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth. The plaque was first disclosed using a dye solution. Participants then rinsed with disclosing solution according to instructions. They had expectorated and rinsed with 10 mL of water for 10 seconds and expectorated again. Plaque was assessed with each tooth being divided into 6 areas including the mesiofacial, facial, distofacial, mesiolingual, lingual and distolingual surfaces. Disclosed plaque was scored as follows: 0= No plaque; 1= Slight flecks of plaque at the cervical margin of the tooth; 2= A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth; 3= A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth; 4= Plaque covering at least 1/3 but less tan 2/3 of the crown of the tooth; 5= Plaque covering 2/3 or more of the crown of the tooth

    Time frame: Baseline, 6,12 and 24 weeks

07

Results

Posted Feb 17, 2017

Participant flow

The participants were recruited at a clinical site in the USA.

Participant flow — Overall Study
MilestoneSodium Bicarbonate Dentrifice0% Sodium Bicarbonate Dentrifice
Started124123
Completed113115
Not completed118
Withdrew: Lost to follow-up31
Withdrew: Withdrawal by subject56
Withdrew: Did not meet study criteria30
Withdrew: Pregnancy01

Outcome measures

PrimaryNumber of Gingival Bleeding Sites at 24 Weeks

Number of gingival bleeding sites were measured as bleeding index via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. A bleeding site was considered as a BI score of 1 or 2.

Time frame:
Baseline, 24 weeks
Reported as:
Mean · number of gingival bleeding sites
Number of Gingival Bleeding Sites at 24 Weeks
number of gingival bleeding sitesSodium Bicarbonate Dentrifice0% Sodium Bicarbonate Dentrifice
Number of Bleeding Sites at Baseline45.13 ± 1.39345.84 ± 1.448
Number of Bleeding sites after 24 weeks18.67 ± 1.14236.39 ± 1.510
Statistical analysis
  • Sodium Bicarbonate Dentrifice vs 0% Sodium Bicarbonate Dentrifice · ANCOVA · p = <0.0001 · Adjusted mean difference: -17.491 · 95% CI -20.317 to -14.664Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
PrimaryModified Gingival Index (MGI) at 24 Weeks

The Modified Gingival Index (MGI) was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

Time frame:
Baseline, 24 weeks
Reported as:
Mean · Units on a scale
Modified Gingival Index (MGI) at 24 Weeks
Units on a scaleSodium Bicarbonate Dentrifice0% Sodium Bicarbonate Dentrifice
Modified Gingival Index at Baseline2.53 ± 0.0172.54 ± 0.018
Modified Gingival Index after 24 weeks2.23 ± 0.0212.43 ± 0.210
Statistical analysis
  • Sodium Bicarbonate Dentrifice vs 0% Sodium Bicarbonate Dentrifice · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.201 · 95% CI -0.237 to -0.165Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
SecondaryNumber of Gingival Bleeding Sites at 6 and 12 Weeks.

Number of gingival bleeding sites were measured as bleeding index via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. A bleeding site was considered as a BI score of 1 or 2.

Time frame:
Baseline, 6 and 12 weeks
Reported as:
Mean · number of gingival bleeding sites
Number of Gingival Bleeding Sites at 6 and 12 Weeks.
number of gingival bleeding sitesSodium Bicarbonate Dentrifice0% Sodium Bicarbonate
Number of Bleeding Sites at Baseline45.13 ± 1.39345.84 ± 1.448
Number of Bleeding Sites after 6 weeks25.40 ± 0.99940.27 ± 1.448
Number of Bleeding sites after 12 weeks20.83 ± 0.91534.23 ± 1.260
SecondaryModified Gingival Index (MGI) at 6 and 12 Weeks.

MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

Time frame:
Baseline, 6 and 12 weeks
Reported as:
Mean · Units on a scale
Modified Gingival Index (MGI) at 6 and 12 Weeks.
Units on a scaleSodium Bicarbonate Dentrifice0% Sodium Bicarbonate Dentrifice
Modified Gingival Index at Baseline2.53 ± 0.0172.54 ± 0.018
Modified Gingival Index after 6 weeks2.28 ± 0.0172.45 ± 0.018
Modified Gingival Index after 12 weeks2.24 ± 0.0182.40 ± 0.018
SecondaryBleeding Index at 6, 12 and 24 Weeks

The Bleeding Index was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system to be used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed

Time frame:
Baseline, 6, 12 and 24 weeks
Reported as:
Mean · Units on a Scale
Bleeding Index at 6, 12 and 24 Weeks
Units on a ScaleSodium Bicarbonate Dentrifice0% Sodium Bicarbonate Dentrifice
Bleeding Index Score at Baseline0.45 ± 0.0140.47 ± 0.014
Bleeding Index Score after 6 weeks0.25 ± 0.0100.41 ± 0.014
Bleeding Index Score after 12 weeks0.21 ± 0.0090.35 ± 0.012
Bleeding Index Score after 24 weeks0.19 ± 0.0120.37 ± 0.014
SecondaryPlaque Control (Overall and Interproximal Dental Plaque Scores) Using Turesky Modification of Quigley &Amp; Hein Plaque Index at 6, 12 and 24 Weeks.

The dental examiner used the Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth. The plaque was first disclosed using a dye solution. Participants then rinsed with disclosing solution according to instructions. They had expectorated and rinsed with 10 mL of water for 10 seconds and expectorated again. Plaque was assessed with each tooth being divided into 6 areas including the mesiofacial, facial, distofacial, mesiolingual, lingual and distolingual surfaces. Disclosed plaque was scored as follows: 0= No plaque; 1= Slight flecks of plaque at the cervical margin of the tooth; 2= A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth; 3= A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth; 4= Plaque covering at least 1/3 but less tan 2/3 of the crown of the tooth; 5= Plaque covering 2/3 or more of the crown of the tooth

Time frame:
Baseline, 6,12 and 24 weeks
Reported as:
Mean · Units on a scale
Plaque Control (Overall and Interproximal Dental Plaque Scores) Using Turesky Modification of Quigley &Amp; Hein Plaque Index at 6, 12 and 24 Weeks.
Units on a scaleSodium Bicarbonate Dentrifice0% Sodium Bicarbonate Dentrifice
Overall Plaque Score at Baseline3.04 ± 0.0193.00 ± 0.019
Overall Plaque Score after 6 weeks2.65 ± 0.0302.98 ± 0.021
Overall Plaque Score after 12 weeks2.55 ± 0.0292.92 ± 0.025
Overall Plaque Score after 24 weeks2.52 ± 0.0322.95 ± 0.020
Interproximal Plaque Score at Baseline3.12 ± 0.0193.08 ± 0.018
Interproximal Plaque Score after 6 weeks2.73 ± 0.0293.05 ± 0.020
Interproximal Plaque Score after 12 weeks2.64 ± 0.0283.01 ± 0.022
Interproximal Plaque Score after 24 weeks2.61 ± 0.0313.03 ± 0.019

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sodium Bicarbonate Dentrifice—0/124 (0%)7/124 (5.6%)
0% Sodium Bicarbonate Dentrifice—0/123 (0%)8/123 (6.5%)
Most frequent other events
Most frequent other events
EventSodium Bicarbonate Dentrifice0% Sodium Bicarbonate Dentrifice
MOUTH INJURYInjury, poisoning and procedural complications3/1243/123
PROCEDURAL PAINInjury, poisoning and procedural complications1/1241/123
THERMAL BURNInjury, poisoning and procedural complications1/1241/123
NASOPHARYNGITISInfections and infestations0/1241/123
ABDOMINAL PAINGastrointestinal disorders0/1241/123
GINGIVAL PAINGastrointestinal disorders0/1241/123
SENSITIVITY OF TEETHGastrointestinal disorders0/1241/123
BRONCHITISInfections and infestations1/1240/123
OVARIAN CYST RUPTUREDRespiratory, thoracic and mediastinal disorders1/1240/123

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sodium Bicarbonate Dentrifice0% Sodium Bicarbonate DentrificeTotal
Mean34.52 ± 13.16237.55 ± 13.97736.03 ± 13.631
Sex: Female, Male
Sex: Female, Male(Participants)Sodium Bicarbonate Dentrifice0% Sodium Bicarbonate DentrificeTotal
Female6972141
Male5551106
08

Study locations

1 site
  • GSK Investigational Site
    Las Vegas, Nevada 89146, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2014
First posted
Aug 4, 2014
Start
Aug 2014
Primary completionActual
Feb 2015
CompletionActual
Mar 2015
Results first posted
Feb 17, 2017
Last update
Apr 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02207907
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 4, 2014
Start date
Aug 2014
Primary completion
Feb 2015
Completion
Mar 2015
Results posted
Feb 17, 2017
Last update
Apr 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sodium Bicarbonate · Sodium Fluoride

Start the discussion